Linked Life Data

19217656

Source:http://linkedlifedata.com/resource/pubmed/id/19217656

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9670
pubmed:dateCreated
2009-4-6
pubmed:abstractText
Peripherally acting mu-opioid receptor antagonists methylnaltrexone and alvimopan are a new class of drugs designed to reverse opioid-induced side-effects on the gastrointestinal system without compromising pain relief. This article gives an overview of the pharmacology, the efficacy, and adverse effects of these drugs. Both compounds seem to be generally well tolerated and effective for the treatment of opioid-related bowel dysfunction and postoperative ileus. Methylnaltrexone recently received approval by the US Food and Drug Administration (FDA) and the European Medicines Agency for treatment of opioid-related bowel dysfunction in patients with advanced illness. Alvimopan was recently approved by the FDA for treatment of postoperative ileus, but the use of the drug is restricted to inpatients because it has been associated with an increased rate of myocardial infarction. Further research should assess the effectiveness and safety of these drugs in clinical practice.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1474-547X
pubmed:author
pubmed:issnType
Electronic
pubmed:day
4
pubmed:volume
373
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1198-206
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus.
pubmed:affiliation
Department of Palliative Care, University Hospital Freiburg, Freiburg, Germany.
pubmed:publicationType
Journal Article, Review